☆ 4.3 Article

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology

JOURNAL OF CARDIOVASCULAR MEDICINE (2016)

Journal

JOURNAL OF CARDIOVASCULAR MEDICINE

Volume 17, Issue -, Pages S93-S104

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.2459/JCM.0000000000000383

Keywords

angiogenesis inhibitors; HER2; epidermal growth factor receptor 2; tyrosine kinase inhibitors

Categories

Cardiac & Cardiovascular Systems

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review

Chao Wang, Yujing Zhang, Tingting Zhang, Jiazhen Xu, Saisai Yan, Bing Liang, Dongming Xing

Summary: Overexpression of EGFR has been linked to various cancers, and drug resistance caused by EGFR mutations is a significant challenge. EGFR dual-target inhibitors show promise in overcoming drug resistance and have higher efficacy compared to single-target inhibitors.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2023)

Add to Collection

Article Medicine, General & Internal

Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis A case report

Ning Liu, Lingnan Zheng, Min Yu, Shuang Zhang

Summary: This case report describes a patient with EGFR-mutant lung adenocarcinoma coexisting with pulmonary tuberculosis. The patient was initially diagnosed with pneumonia-like pulmonary adenocarcinoma and later confirmed to have active tuberculosis. The patient received a combination therapy of gefitinib and anti-TB treatment, leading to stable disease status and survival.

MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition

Thushara W. Madanayake, Eric A. Welsh, Lancia N. F. Darville, John M. Koomen, Charles E. Chalfant, Eric B. Haura, Timothy J. Robinson

Summary: We have developed a novel method to inhibit EGFR signaling using custom ASOs to induce exon skipping and drive the expression of dominant negative mRNA isoforms of EGFR. Our in vivo experiments showed that ASOs were highly effective in inhibiting colony formation, cell viability, and migration in EGFR mutant NSCLC. Importantly, ASOs maintained their efficacy in erlotinib-resistant subclones and wild-type EGFR overexpressing models, where erlotinib had no significant effect. By directly targeting the EGFR kinase domain, ASOs resulted in maximal inhibition of EGFR phosphorylation and downstream signaling in both EGFR mutant and erlotinib-resistant cells. Furthermore, our study confirmed the EGFR-specific therapeutic mechanism of ASOs in EGFR-independent NSCLC models. Further investigation of the synergy between ASOs and existing tyrosine kinase inhibitors could provide new clinical models to improve EGFR-targeted therapies for NSCLC patients, both mutant and wild-type.

NUCLEIC ACID THERAPEUTICS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study

Ryo Miyata, Masatsugu Hamaji, Atsushi Kawaguchi, Yumeta Shimazu, Masaki Ikeda, Masashi Ishikawa, Hidenao Kayawake, Toshi Menju, Masashi Kobayashi, Norihito Okumura, Yasuto Sakaguchi, Makoto Sonobe, Akira Matsumoto, Tsuyoshi Shoji, Hiromichi Katakura, Ryota Sumitomo, Cheng-Long Huang, Mamoru Takahashi, Akihiro Aoyama, Yusuke Muranishi, Tomoya Kono, Ryo Miyahara, Naoki Date, Takuji Fujinaga, Ei Miyamoto, Tatsuo Nakagawa, Takahisa Fukada, Hiroaki Sakai, Hiroshi Date

Summary: This study analyzed the long-term survival outcomes and prognostic factors of patients with postoperative recurrent EGFR-mutated lung adenocarcinoma who received EGFR-TKIs as first-line treatment. The study found that first-line EGFR-TKI treatment was generally associated with favorable survival outcomes. EGFR ex 21 L858R mutation may be an important prognostic factor for shorter progression-free survival (PFS).

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Modulation of Pathological Pain by Epidermal Growth Factor Receptor

Jazlyn P. Borges, Katrina Mekhail, Gregory D. Fairn, Costin N. Antonescu, Benjamin E. Steinberg

Summary: Chronic pain is a major public health issue that is often resistant to conventional analgesics. Recent studies have implicated the epidermal growth factor receptor (EGFR) signaling pathway in chronic pain, suggesting potential therapeutic targets for this devastating condition.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation

Yu-Jin Wang, Qing-Wen Wang, Dong-Hu Yu, Cong-Kuan Song, Zi-Xin Guo, Xiao-Ping Liu, Chen Chen, Jie Yao, Ai-Fen Wang, Wei-Dong Hu

Summary: The correlation between Osteopontin (OPN) and EGFR affects the sensitivity of lung adenocarcinoma (LUAD) cells to the first-generation TKI gefitinib, suggesting OPN as a potential target for molecular therapy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors' Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma

Lijuan Zhang, Meng Tian, Jiamao Lin, Jianbo Zhang, Haiyong Wang, Zhenxiang Li

Summary: The interaction between ER beta 1 and ER beta 5 in lung adenocarcinoma affects non-genomic signaling and resistance to EGFR TKIs. Cytoplasmic ER beta 1 may contribute to EGFR TKI resistance, and PC9/ER beta 1/5 cells show higher resistance to gefitinib.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis

Wilson Sim, Sneha Rajiv Jain, Wen Hui Lim, Yip Han Chin, Cheng Han Ng, Nicholas Syn, Kang Shiong Goh, Ross Soo, Lingzhi Wang, Boon Cher Goh

Summary: The study found that the interaction between EGFR TKIs and PPIs/H2RAs in NSCLC patients has an impact on survival outcomes. Patients treated only with EGFR TKIs have better overall survival and progression-free survival, while concurrent use of PPIs results in worsening outcomes. There were no significant differences in adverse effects between different acid suppression medications.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Binding of tyrosine kinase inhibitor to epidermal growth factor receptor: surface-enhanced infrared absorption microscopy reveals subtle protein secondary structure variations

Paolo Zucchiatti, Giovanni Birarda, Andrea Cerea, Marta S. Semrau, Aliaksandr Hubarevich, Paola Storici, Francesco De Angelis, Andrea Toma, Lisa Vaccari

Summary: This study demonstrates the potential of SEIRA microscopy in detecting subtle secondary structure modifications associated with the binding of Lapatinib to EGFR. By optimizing techniques and data analysis, the researchers successfully identified secondary structure modifications in EGFR related to a few amino acids.

NANOSCALE (2021)

Add to Collection

Review Oncology

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo

Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.

CANCERS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition

Yusuke Masuo, Ken-ichi Fujita, Kazuhiro Shimada, Noriho Iida, Tomohiko Wakayama, Yukio Kato, Aya Hasan Alshammari

Summary: This study explains the occurrence of hand-foot skin reaction (HFSR) in patients treated with tyrosine kinase inhibitors (TKIs) by examining keratinocyte toxicity and VEGFR-2 inhibition.

BIOCHEMICAL PHARMACOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy

Cancan Lyu, Yuanchao Ye, Maddison M. Lensing, Kay-Uwe Wagner, Ronald J. Weigel, Songhai Chen

Summary: In HER2(+) breast cancer, overactivation of HER2 leads to aberrant G(i/o)-GPCR signaling, promoting cancer progression and resistance to HER2-targeted therapy. Pharmacologically deactivating GPCR signaling can block tumor growth and enhance therapeutic efficacy.

JCI INSIGHT (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review

Qinchao Wu, Baochen Bai, Chao Tian, Daisong Li, Haichu Yu, Bingxue Song, Bing Li, Xianming Chu

Summary: The introduction of novel targeted drugs has significantly reduced cancer-related mortality and increased survival rates, but they also come with unexpected cardiac side effects. Understanding and exploring management measures for these side effects are crucial for maximizing the benefits of these drugs.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

Add to Collection

Article Respiratory System

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study

Jingwen Wei, Jing Xiang, Yue Hao, Jinfei Si, Wenxian Wang, Fangyin Li, Zhengbo Song

Summary: This study retrospectively analyzed the anemia status of NSCLC patients with EGFR mutations and found that baseline anemia is associated with poor prognosis. Patients without baseline anemia and those with grade < 2 anemia had longer overall survival.

BMC PULMONARY MEDICINE (2022)

Add to Collection

Article Chemistry, Analytical

Inside-Out-Oriented Cell Membrane Biomimetic Magnetic Nanoparticles for High-Performance Drug Lead Discovery

Yusi Bu, Xiaolin Zhang, Aihong Zhu, Linhao Li, Xiaoyu Xie, Sicen Wang

Summary: Inside-out cell membrane-coated nanoparticles were prepared for screening tyrosine kinase inhibitors and successfully targeted potential antitumor compounds from lung adenocarcinoma. This novel approach enhances drug screening efficiency and broadens possibilities for drug lead discovery in the future.

ANALYTICAL CHEMISTRY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prognostic impact of diabetes in chronic and acute heart failure

Stefano Ghio, Valentina Mercurio, Andrea Attanasio, Gaetano Asile, Carlo Gabriele Tocchetti, Stefania Paolillo

Summary: There is a strong bidirectional relationship between diabetes mellitus (DM) and heart failure (HF), with DM activating multiple molecular and pathophysiological mechanisms that can damage the heart in the long term. However, the prognostic role of DM in chronic and acute HF is still unclear, with gaps in evidence due to the heterogeneity of patient phenotypes and the necessity to better characterize individual patients and their comorbidities. This review aims to summarize the negative impact of DM on HF and analyze available data on the prognostic implications in both chronic and acute HF.

HEART FAILURE REVIEWS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis

Frank L. Dini, Nicola Riccardo Pugliese, Pietro Ameri, Umberto Attanasio, Roberto Badagliacca, Michele Correale, Valentina Mercurio, Carlo Gabriele Tocchetti, Piergiuseppe Agostoni, Alberto Palazzuoli

Summary: Right heart failure is a clinical syndrome characterized by symptoms and signs caused by dysfunction and/or overload of the right heart structures, mainly the right ventricle, resulting in systemic venous hypertension, peripheral edema, and decreased tissue perfusion ability of the right heart. RHF can be caused by various cardiac diseases, including coronary artery disease, hypertension, valvular heart disease, cardiomyopathies, and myocarditis. Early recognition and identification of the underlying cause of RHF are crucial for effective treatment and prognosis improvement.

HEART FAILURE REVIEWS (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

G. A. Lee, S. Aktaa, E. Baker, C. P. Gale, Israa F. Yaseen, G. Gulati, R. Asteggiano, S. Szmit, A. Cohen-Solal, A. Abdin, W. Jurczak, P. Garrido Lopez, A. L. Sverdlov, C. G. Tocchetti, A. Barac, I. Parrini, P. Zamorano, Z. Iakobishvili, R. Pudil, L. Badimon, A. M. Kirby, A. H. Blaes, D. Farmakis, G. Curigliano, R. Stephens, A. R. Lyon, T. Lopez-Fernandez

Summary: The aim of this study is to develop quality indicators (QIs) for evaluating the prevention and management of cancer therapy-related cardiovascular toxicity. The study followed the ESC methodology and involved identifying key domains of care, conducting a literature review, and selecting the final set of indicators. The study was conducted in collaboration with various associations and resulted in the selection of 5 main and 9 secondary QIs across five domains of care. Overall, this study is of great importance in improving clinical practice and patient outcomes.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors

Antonella Meloni, Christian Cadeddu, Lucia Cugusi, Maria Pia Donataccio, Martino Deidda, Susanna Sciomer, Sabina Gallina, Cristina Vassalle, Federica Moscucci, Giuseppe Mercuro, Silvia Maffei

Summary: Metabolic syndrome is a clinical condition characterized by the aggregation of major risk factors for cardiovascular disease and type 2 diabetes, including dyslipidemia, high blood pressure, abnormal blood sugar, and abdominal obesity. These risk factors have an independent effect but become synergistic when combined, leading to a doubled risk of cardiovascular diseases and a 1.5-fold increase in all-cause mortality. This article explores gender differences in the epidemiology, etiology, pathophysiology, and clinical expression of metabolic syndrome components, as well as gender differences in new biochemical markers of metabolic syndrome and cardiovascular risk.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC

Marco Metra, Marianna Adamo, Daniela Tomasoni, Alexandre Mebazaa, Antoni Bayes-Genis, Magdy Abdelhamid, Stamatis Adamopoulos, Stefan D. Anker, Johann Bauersachs, Yuri Belenkov, Michael Boehm, Tuvia Ben Gal, Javed Butler, Alain Cohen-Solal, Gerasimos Filippatos, Finn Gustafsson, Loreena Hill, Tiny Jaarsma, Ewa A. Jankowska, Mitja Lainscak, Yuri Lopatin, Lars H. Lund, Theresa McDonagh, Davor Milicic, Brenda Moura, Wilfried Mullens, Massimo Piepoli, Marija Polovina, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Gianluigi Savarese, Petar Seferovic, Rajan Sharma, Thomas Thum, Carlo G. Tocchetti, Sophie Van Linthout, Cristiana Vitale, Stephan Von Haehling, Maurizio Volterrani, Andrew J. S. Coats, Ovidiu Chioncel, Giuseppe Rosano

Summary: Acute heart failure is a common cause of urgent hospital admissions. Optimal management before and after discharge is critical to prevent rehospitalization and improve outcomes.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology

Marco Metra, Daniela Tomasoni, Marianna Adamo, Antoni Bayes-Genis, Gerasimos Filippatos, Magdy Abdelhamid, Stamatis Adamopoulos, Stefan D. Anker, Laura Antohi, Michael Boehm, Frieder Braunschweig, Tuvia Ben Gal, Javed Butler, John G. F. Cleland, Alain Cohen-Solal, Kevin Damman, Finn Gustafsson, Loreena Hill, Ewa A. Jankowska, Mitja Lainscak, Lars H. Lund, Theresa McDonagh, Alexandre Mebazaa, Brenda Moura, Wilfried Mullens, Massimo Piepoli, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Gianluigi Savarese, Petar Seferovic, Rajan Sharma, Carlo Gabriele Tocchetti, Mehmet Birhan Yilmaz, Cristiana Vitale, Maurizio Volterrani, Stephan von Haehling, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe Rosano

Summary: Episodes of worsening symptoms and signs are common in patients with chronic heart failure and are associated with negative outcomes. Diuretic therapy is often necessary, along with additional treatments such as guideline-recommended medical therapy. Prevention of worsening heart failure is crucial, and early and rapid administration of appropriate treatments can help achieve this goal. The clinical consensus statement by the Heart Failure Association of the European Society of Cardiology provides an update on the management and prevention of worsening heart failure in clinical practice.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Add to Collection

Review Oncology

Circulating Vitamin D Level and Its Impact on Mortality and Recurrence in Stage III Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

Alessandro Ottaiano, Sergio Facchini, Mariachiara Santorsola, Guglielmo Nasti, Gaetano Facchini, Liliana Montella, Nicola Maurea, Marco Cascella, Domenico Iervolino, Bianca Arianna Facchini, Monica Montopoli, Pierluigi Consolo, Vincenzo Quagliariello, Luca Rinaldi, Massimiliano Berretta

Summary: We conducted a systematic review and meta-analysis to investigate the association between pre-operative vitamin D levels and time-to-outcome in stage III colorectal cancer patients. The results showed that patients with lower levels of vitamin D had an increased risk of death and recurrence. These findings suggest that a low vitamin D concentration negatively impacts the time-to-outcome in stage III colorectal cancer.

CANCERS (2023)

Add to Collection

Review Oncology

PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology

Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, Martina Iovine, Maria Laura Canale, Carlo Maurea, Vienna Giordano, Andrea Paccone, Alessandro Inno, Nicola Maurea

Summary: This review summarizes the pleiotropic effects of PCSK9 in heart failure, atherosclerosis, and cancer immune recognition, and outlines its ability to represent a new pharmacological target in patients who develop ICIs-related atherosclerosis to reduce cardiovascular mortality and to improve overall survival.

CANCERS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples

Erberto Carluccio, Frank L. Dini, Michele Correale, Giuseppe Dattilo, Michele Ciccarelli, Francesca Vannuccini, Stefano Sforna, Giuseppe Pacileo, Daniele Masarone, Laura Scelsi, Stefano Ghio, Carlo Gabriele Tocchetti, Valentina Mercurio, Natale Daniele Brunetti, Savina Nodari, Giuseppe Ambrosio, Alberto Palazzuoli

Summary: In patients with heart failure with reduced ejection fraction, treatment with sacubitril-valsartan may be more effective in reversing left ventricular remodeling compared to other renin-angiotensin system inhibitors.

CLINICAL RESEARCH IN CARDIOLOGY (2023)

Add to Collection

Correction Cardiac & Cardiovascular Systems

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (vol 23, pg e333, 2022)

Alexander R. Lyon, Teresa Lopez-Fernandez, Liam S. Couch, Riccardo Asteggiano, Marianne C. Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan F. Dent, Dimitrios Farmakis, Sofie A. Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel Lenihan, Javid Moslehi, Brenda Moura, Sonja S. Salinger, Richard Stephens, Thomas M. Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J. H. van der Pal

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2023)

Add to Collection

Correction Cardiac & Cardiovascular Systems

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (vol 43, pg 4229, 2022)

Alexander R. Lyon, Teresa Lopez-Fernandez, Liam S. Couch, Riccardo Asteggiano, Marianne C. Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan F. Dent, Dimitrios Farmakis, Sofie A. Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel Lenihan, Javid Moslehi, Brenda Moura, Sonja S. Salinger, Richard Stephens, Thomas M. Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J. H. van der Pal

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Non-invasive evaluation of pulmonary capillary wedge pressure using the left atrial expansion index in mitral valve stenosis, prosthesis and repair

Davide Genovese, Marco Previtero, Giacomo Prete, Anna Carrer, Laura De Michieli, Luigi Paolo Badano, Denisa Muraru, Carlo Cernetti, Donato Mele, Giuseppe Tarantini, Sabino Iliceto, Martina Perazzolo Marra

Summary: This study aimed to assess the left atrial expansion index (LAEI) measured through transthoracic echocardiography as a novel parameter for estimating pulmonary capillary wedge pressure (PCWP) in patients with mitral valve stenosis, prosthesis, and surgical repair. The results showed that LAEI correlated logarithmically with PCWP, and the log-transformed LAEI (lnLAEI) had a good linear association with PCWP. lnLAEI was found to be an independent determinant of PCWP and provided added predictive value over conventional clinical and echocardiographic variables.

INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function

Michele Ciccarelli, Ines Falcao Pires, Johann Bauersachs, Luc Bertrand, Christophe Beauloye, Dana Dawson, Nazha Hamdani, Denise Hilfiker-Kleiner, Linda W. van Laake, Frank Lezoualc'h, Wolfgang A. Linke, Ida G. Lunde, Peter P. Rainer, Antonella Rispoli, Valeria Visco, Albino Carrizzo, Matteo Dal Ferro, Davide Stolfo, Jolanda van der Velden, Serena Zacchigna, Stephane Heymans, Thomas Thum, Carlo Gabriele Tocchetti

Summary: This scientific statement highlights the challenges in acute heart failure (AHF) treatment and emphasizes the need for research models and understanding of its mechanisms. It also discusses potential molecular targets for new therapeutic perspectives.

CARDIOVASCULAR RESEARCH (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Left atrial expansion index measured with cardiovascular magnetic resonance estimates pulmonary capillary wedge pressure in dilated cardiomyopathy

Davide Genovese, Laura De Michieli, Giacomo Prete, Manuel De Lazzari, Marco Previtero, Donato Mele, Carlo Cernetti, Giuseppe Tarantini, Sabino Iliceto, Martina Perazzolo Marra

Summary: This study aimed to evaluate the feasibility of using the left atrial expansion index (LAEI) calculated from echocardiography as a non-invasive parameter for estimating pulmonary capillary wedge pressure (PCWP) in patients with dilated cardiomyopathy (DCM). The study found a strong linear correlation between LAEI and PCWP, and demonstrated that LAEI can accurately identify patients with high PCWP.

JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2023)

Add to Collection

Article Pharmacology & Pharmacy

Antineoplastic drugs inducing cardiac and vascular toxicity - An update

Serena Barachini, Sandra Ghelardoni, Zoltan V. Varga, Radwa A. Mehanna, Maria Magdalena Montt-Guevara, Peter Ferdinandy, Rosalinda Madonna

Summary: With the improvement in cancer prognosis, there has been an increase in survival rate among cancer survivors. However, the use of anti-neoplastic drugs has led to an increase in morbidity among these survivors due to cardiovascular complications. These complications include arrhythmias, myocardial ischemia, heart failure, arterial hypertension, thromboembolic events, and accelerated atherosclerosis. The drugs not only target cancer cells but also affect normal cells within the cardiovascular system, leading to toxicity.

VASCULAR PHARMACOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.